528560-93-2 Telmisartan methyl ester AKSci B350
 
 
Loading Please Wait...
  B350    
Telmisartan methyl ester
, 98% (HPLC)
 
Methyl 4’-[[2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]methyl]biphenyl-2-carboxylate




IDENTITY
CAS Number:528560-93-2
MDL Number:MFCD09841005
MF:C34H32N4O2
MW:528.64
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:LCMS, FT-IR, HPLC
Physical Form:White crystalline powder
Melting Point:183-186°C
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Application(s):Angiotensin II receptor antagonist (ARB)

REVIEW

 Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPARγ activators.

REFERENCES
[1]Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25.
[2] Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29.
[3] Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501.
[4] Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of January 19, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Angiotensin Receptor Blockers


PubChem